Navigation Links
Key milestone towards the development of a new clinically useful antibiotic

Scientists have identified the genes necessary for making a highly potent and clinically unexploited antibiotic in the fight against multi-resistant pathogens.

"Lantibiotics are antibiotic molecules produced by soil bacteria, and we are studying probably the most potent one known, microbisporicin, which is active against many different pathogens," said Professor Mervyn Bibb from the John Innes Centre, co-author on the paper to be published in PNAS.

"Our study has allowed us to understand how the antibiotic is made by a bacterium that was first isolated from Indonesian soil. Now we can engineer the bacterium to make similar but better molecules, and lots of them."

"For example, we can take rational approaches to improve its pharmacological properties, such as its stability in the blood stream and how it distributes into tissues."

The producing bacterium, Microbispora corallina, is difficult to work with. It grows very slowly and no tools existed for its genetic manipulation. PhD student Lucy Foulston developed the tools herself. She then took advantage of new developments in genome sequencing to identify and then isolate the M. corallina gene cluster responsible for microbisporicin production.

This allowed her to analyse how the bacterium makes the molecule and the functions of the genes involved. Notably, she was able to identify the genes responsible for giving microbisporicin some of its unique features.

The antibiotic molecule binds to a well established target in the pathogenic bacteria it kills, and as yet there are no signs of resistance towards it.

Microbisporicin is very effective at killing disease-causing bacteria, including Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant pathogens.

"This molecule is already in late preclinical-phase trials and in animal models has shown to be more effective than the current drugs of last resort, linezolid and vancomycin," said Professor Bibb.

"We believe that this study will make a major contribution to the future clinical development of this exciting antibiotic, and the derivatives that can be made using the knowledge and technology that we have developed."


Contact: Zoe Dunford
Norwich BioScience Institutes

Related biology technology :

1. RSB Spine, LLC, Announces Record Second-Quarter 2010 Revenue and Monthly Sales Milestone
2. NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
3. Copan Installs Milestone 30th Walk-Away Specimen Processor (WASP)
4. Xofts Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations
5. Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers
6. Advanced Life Sciences Previews 2010 Milestones
7. Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
8. Microbix Pipeline Set To Reach Milestones In 2010
9. BioSoteria Drug Safety Newsletter Reaches Milestone
10. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
11. Major Milestone Achieved - Berlin Heart EXCOR Pediatric IDE Study
Post Your Comments:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):